MedTrace Logo

Observational Study Assessing Outcomes, Treatment Patterns and Related Costs in Patients in Bullous Pemphigoid

NCT02837965 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 149

Last updated 2024-02-23

No results posted yet for this study

Summary

The study is an observational, multi-center, prospective, non-interventional and open-label data collection study assessing outcomes, treatment patterns, adverse events and costs in patients diagnosed with bullous pemphigoid. The patient enrollment period will be 1 year with a follow-up (observation period) of 1 year for each patient. Four dermatology centres in France will participate. The hypothesis to be answered by the study is that superpotent topical corticosteroid therapy is properly used to treat bullous pemphigoid in real-world life as recommended by French guidelines and whether this treatment influences the medical costs by comparison with systemic therapies (e.g. methotrexate or prednisone).

Conditions

  • Bullous Pemphigoid

Interventions

DRUG

treatment with topical superpotent corticosteroid therapy

DRUG

treatment with systemic therapy (methotrexate)

DRUG

treatment systemic therapy (prednisone)

DRUG

treatment with systemic therapy (prednisone)

DRUG

treatment with systemic therapy (doxycycline)

Sponsors & Collaborators

  • CHU de Reims

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-26
Primary Completion
2018-07-12
Completion
2018-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02837965 on ClinicalTrials.gov